RTP Mobile Logo
Survey Says: A Grand Rounds Activity Focused on Key Management and Research Issues in Non-Small Cell Lung Cancer
Released July 2012

Recorded proceedings from a Grand Rounds series held at institutions throughout the United States. Featuring the perspectives of Dr Corey J Langer. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE

    This activity is intended for medical, surgical and radiation oncologists, thoracic surgeons and other allied professionals involved in the treatment of non-small cell lung cancer (NSCLC).

    OVERVIEW OF ACTIVITY

    Representing one of the most dynamic areas of medical oncology today, NSCLC has witnessed the recent emergence of numerous data sets affecting current treatment decision-making for patients diagnosed with this lethal disease. Several consensus- and evidence-based treatment guidelines are available and aim to assist clinicians with making management decisions in the face of this rapidly evolving clinical environment. But despite the existence of these tools, many areas of controversy persist within academic and community settings. These video proceedings from an interactive Grand Rounds activity combine the perspectives of 7 lung cancer investigators on a number of controversial issues in the diagnosis and treatment of NSCLC with a review of emerging research information in this area to assist medical oncologists and other allied cancer professionals with the formulation of up-to-date clinical management strategies.

    LEARNING OBJECTIVES

    • Counsel patients with localized NSCLC about the risk-adjusted, long-term clinical effects of adjuvant chemotherapy.
    • Use biomarkers, clinical characteristics and tumor histology to select individualized front-line and subsequent treatment approaches for patients with metastatic NSCLC.
    • Identify patients with metastatic NSCLC who may experience clinical benefit from the addition of maintenance biologic therapy and/or chemotherapy.
    • Recognize the effects of NSCLC tumor-specific mutations on relative response or resistance to treatment with EGFR tyrosine kinase inhibitors, monoclonal antibodies and other emerging molecular-targeted agents.
    • Counsel appropriately selected patients about the availability of ongoing clinical trial participation.
    • Employ case-based learning to refine or validate your existing NSCLC treatment algorithms.

    ACCREDITATION STATEMENT

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY

    This CME activity consists of a video component. The participant should watch the video.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Chandra P Belani, MD

    Miriam Beckner Distinguished Professor of Medicine
    Penn State College of Medicine
    Deputy Director, Penn State Hershey Cancer Institute
    Hershey, Pennsylvania

    Advisory Committee: Genentech BioOncology, Lilly USA LLC, Pfizer Inc; Consulting Agreements: Genentech BioOncology, Lilly USA LLC.

    Edward S Kim, MD
    Chair, Department of Solid Tumor Oncology and Investigational Therapeutics
    Donald S Kim Distinguished Chair for Cancer Research
    Levine Cancer Institute
    Carolinas Healthcare System
    Charlotte, North Carolina

    Consulting Agreements: Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, Lilly USA LLC, OSI Oncology; Paid Research: Genentech BioOncology, Lilly USA LLC.

    Corey J Langer, MD
    Director of Thoracic Oncology, Abramson Cancer Center
    Professor of Medicine, University of Pennsylvania
    Vice Chair, Radiation Therapy Oncology Group
    Philadelphia, Pennsylvania

    Advisory Committee and Consulting Agreements: Allos Therapeutics, ARIAD Pharmaceuticals Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, OSI Oncology, Pfizer Inc; Data and Safety Monitoring Committee: Amgen Inc.

    Alan B Sandler, MD
    Professor of Medicine
    Division Chief, Hematology and Medical Oncology
    DeArmond Chair for Clinical Cancer Research
    Co-Director, Clinical Management Research
    Associate Director for Clinical Research
    Knight Cancer Institute
    Oregon Health and Science University
    Portland, Oregon

    Advisory Committee: Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, Lilly USA LLC, Roche Laboratories Inc; Consulting Agreements: Allos Therapeutics, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, Lilly USA LLC, Roche Laboratories Inc; Paid Research: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech BioOncology, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Pfizer Inc; Speakers Bureau: Genentech BioOncology, Lilly USA LLC.

    Lecia V Sequist, MD, MPH
    Assistant Professor of Medicine
    Harvard Medical School
    Center for Thoracic Cancers
    Massachusetts General Hospital Cancer Center
    Boston, Massachusetts

    Advisory Committee: Daiichi Sankyo Inc, GlaxoSmithKline; Paid Research: ArQule Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Clovis Oncology, Daiichi Sankyo Inc, Genentech BioOncology, GlaxoSmithKline, Lilly USA LLC, Merrimack Pharmaceuticals, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi.

    Mark A Socinski, MD
    Professor of Medicine and Thoracic Surgery
    Director, Lung Cancer Section
    Division of Hematology/Oncology
    Co-Director, UPMC Lung Cancer Center of Excellence
    Co-Director, Lung and Thoracic Malignancies Program
    University of Pittsburgh, UPMC Cancer Pavilion
    Pittsburgh, Pennsylvania

    Paid Research: Celgene Corporation, Genentech BioOncology, Lilly USA LLC, Pfizer Inc, Synta Pharmaceuticals Corp; Speakers Bureau: Genentech BioOncology, Lilly USA LLC.

    Heather Wakelee, MD
    Assistant Professor of Medicine
    Division of Oncology
    Stanford University School of Medicine
    Stanford Cancer Institute
    Stanford, California

    Paid Research: ArQule Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Exelixis Inc, Genentech BioOncology, Lilly USA LLC, Novartis Pharmaceuticals Corporation, Pfizer Inc, Regeneron Pharmaceuticals.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Astellas, Genentech BioOncology and Lilly USA LLC.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Netscape 7.x or newer, Internet Explorer 5.x or newer, or Firefox
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: July 2012
    Expiration date: July 2013

Acknowledge and close

Watch video
(WiFi is recommended for best performance):